Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/500μg vs Fluticasone Propionate 500μg in Patients with Corticosteroid-Dependent Asthma V: Results

被引：0
|
作者：
Willem R. Pieters
Bo Lundbäck
Seema Sondhi
Martin J. Price
Robert M.A. Thwaites
机构：
[1] Elkerliek Ziekenhuis,Respiratory Unit
[2] National Institute for Working Life,Global Health Outcomes
[3] Glaxo Wellcome,undefined
来源：
PharmacoEconomics | 1999年 / 16卷
关键词：
Asthma; Adis International Limited; Fluticasone Propionate; Salmeterol; Formoterol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Methods: An economic analysis was performed to compare the cost effectiveness of a new formulation combining salmeterol 50μg and fluticasone propionate 500μg in a multidose dry powder (Diskus™) inhaler (n = 167) with that of fluticasone propionate (FP) 500μg (n = 165) also delivered via the Diskus™ in patients with corticosteroid-dependent asthma. Clinical data were obtained from a recent European multicentre trial; the economic analysis adopted a Swedish healthcare perspective.
引用
收藏
页码：29 / 34
页数：5
相关论文
共 49 条
  • [21] Cost-Effectiveness and Cost-Utility of Beclomethasone/Formoterol versus Fluticasone Propionate/Salmeterol in Patients with Moderate to Severe Asthma
    Simone Gerzeli
    Carla Rognoni
    Silvana Quaglini
    Maria Caterina Cavallo
    Giovanni Cremonesi
    Alberto Papi
    Clinical Drug Investigation, 2012, 32 : 253 - 265
  • [22] The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the diskus inhaler for the treatment of COPD
    Hanania, NA
    Darken, P
    Horstman, D
    Reisner, C
    Lee, B
    Davis, S
    Shah, T
    CHEST, 2003, 124 (03) : 834 - 843
  • [23] Fluticasone propionate 50 μg BID versus 100 μg BID in the treatment of children with persistent asthma
    Katz, Y
    Lebas, FX
    Medley, H
    Robson, R
    CLINICAL THERAPEUTICS, 1998, 20 (03) : 424 - 437
  • [24] Clinical Equivalence of a Salmeterol/Fluticasone Propionate Combination Product (50/500μg) Delivered via a Chlorofluorocarbon-Free Metered-Dose Inhaler with the Diskus™ in Patients with Moderate to Severe Asthma
    J. A. van Noord
    H. Lill
    T. Carrillo Diaz
    A. P. Greefhorst
    P. Davies
    Clinical Drug Investigation, 2001, 21 : 243 - 255
  • [25] Oropharyngeal candidiasis with dry-powdered fluticasone propionate:: 500 μg/day versus 200 μg/day
    Kurt, E.
    Yidirim, H.
    Kiraz, N.
    Orman, A.
    Metintas, M.
    Akgun, Y.
    Erginel, S.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2008, 36 (01) : 17 - 20
  • [26] Mometasone furoate vs fluticasone propionate with salmeterol: multivariate analysis of resource use and asthma-related charges
    Navaratnam, Prakash
    Friedman, Howard S.
    Urdaneta, Eduardo
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 2895 - 2901
  • [27] Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma
    Jenkins, C
    Woolcock, AJ
    Saarelainen, P
    Lundbäck, B
    James, MH
    RESPIRATORY MEDICINE, 2000, 94 (07) : 715 - 723
  • [28] Cost-Efficacy Analysis of Fluticasone Propionate versus Zafirlukast in Patients with Persistent Asthma
    Rogelio Menendez
    Richard H. Stanford
    Lisa Edwards
    Christopher Kalberg
    Kathleen Rickard
    PharmacoEconomics, 2001, 19 : 865 - 874
  • [29] Cost Effectiveness of Inhaled Fluticasone Propionate vs Inhaled Triamcinolone Acetonide in the Treatment of Persistent Asthma
    Richard H. Stanford
    Lisa D. Edwards
    Kathleen A. Rickard
    Clinical Drug Investigation, 2000, 20 : 237 - 244
  • [30] Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 μg) combination product (SAS 40023)
    Baumgarten, C
    Geldszus, R
    Behre, U
    Peslis, N
    Trautmann, M
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2002, 7 (01) : 1 - 7
12345